Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

Expert Opinion on Drug Metabolism & Toxicology
José A G AgúndezCarmen Martínez


Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib. This impairment in drug biodisposition alters drug pharmacokinetics, with carriers of detrimental mutations displaying increased values of AUC and decreased drug clearance. Individuals carrying the gene variants CYP2C8*3 (rs11572080; rs10509681), CYP2C9*2 (rs1799853) or CYP2C9*3 (rs1057910) show increased risk of developing acute gastrointestinal bleeding during the use of NSAID that are CYP2C8 or CYP2C9 substrates. However, it is not known whether parent drugs or products of alternative metabolic pathways are responsible for bleeding. We present an overview of the current knowledge of relevant polymorphisms of CYP2C8 and CYP2C9 genes, their association with NSAID metabolism and pharmacokinetics and a meta-analysis that confirms the clinical significance of these gene variations with regard to gastrointestinal bleeding.


Jan 1, 1987·European Journal of Clinical Pharmacology·C J RichardsonR K Verbeeck
Mar 1, 1986·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A J HuttR L Smith
Apr 1, 1995·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J A AgúndezJ Benítez
Feb 1, 1995·Clinical Pharmacokinetics·N M Davies
Mar 1, 1995·Clinical Pharmacokinetics·M LevyB Rosenkranz
Feb 1, 1994·Clinical Pharmacokinetics·K T OlkkolaM J Mattila
Aug 1, 1996·Pharmacogenetics·T H Sullivan-KloseJ A Goldstein
Mar 11, 1998·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·C ChesnéT Sauter
Apr 11, 2001·Toxicological Sciences : an Official Journal of the Society of Toxicology·C KingM Braun
May 25, 2001·European Journal of Clinical Pharmacology·E García-MartínJ A Agúndez
Aug 8, 2001·British Journal of Clinical Pharmacology·E RahmeJ LeLorier
Oct 5, 2001·Journal of Clinical Pharmacology·A KarimR C Hubbard
Oct 27, 2001·British Journal of Clinical Pharmacology·M G ScordoM Ingelman-Sundberg
Jan 17, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R JaggiR G Dickinson
Feb 7, 2002·European Journal of Clinical Pharmacology·U YasarM L Dahl
May 23, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rita A HalpinThomas A Baillie
Oct 24, 2002·British Journal of Clinical Pharmacology·Mia SandbergErik Eliasson
Nov 19, 2002·Biochemical and Biophysical Research Communications·Umit YasarAnders Rane
Jan 22, 2003·British Journal of Clinical Pharmacology·Julia KirchheinerJürgen Brockmöller
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ji Y ZhangAlan P Breau
Apr 17, 2003·European Journal of Clinical Pharmacology·Craig R LeeJoyce A Goldstein
Jul 23, 2003·Current Drug Metabolism·Wei Tang
Aug 2, 2003·Pharmacogenetics·Julia KirchheinerJürgen Brockmöller
Jun 8, 2004·Current Drug Metabolism·Jose A G Agundez
Jul 2, 2004·Clinical Pharmacology and Therapeutics·Rosane Vianna-JorgeGuilherme Suarez-Kurtz
Jul 31, 2004·Pharmacogenetics·Joyce BlaisdellJoyce A Goldstein
Sep 17, 2004·Clinical Pharmacology and Therapeutics·Feng ZhaoSoo Chin Lee
Dec 21, 2004·British Journal of Clinical Pharmacology·Yifan ZhangHui Zhou
Dec 21, 2004·British Journal of Clinical Pharmacology·Carmen MartínezJosé A G Agúndez
Jan 8, 2005·Clinical Pharmacology and Therapeutics·Julia Kirchheiner, Jürgen Brockmöller
Feb 11, 2005·American Journal of Medical Genetics. Part a·Cheryl A M AndersonArno G Motulsky
Feb 17, 2005·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Simon SandersonJulian Higgins
Feb 18, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hiroyuki HichiyaJun-ichi Sawada

❮ Previous
Next ❯


Oct 10, 2012·The Pharmacogenomics Journal·J E WyattS Harirforoosh
Feb 18, 2012·Pharmacogenetics and Genomics·Li GongTeri E Klein
May 28, 2010·Pharmacogenomics·Ulrike M StamerFrank Stüber
May 30, 2013·Expert Opinion on Pharmacotherapy·Christian Hillstrom, Jan G Jakobsson
Apr 10, 2013·Expert Opinion on Drug Metabolism & Toxicology·José A G AgúndezFélix Javier Jiménez-Jiménez
Aug 2, 2013·Expert Opinion on Drug Metabolism & Toxicology·Elena García-MartínJosé A G Agúndez
Apr 9, 2011·Expert Opinion on Drug Metabolism & Toxicology·José Ag AgúndezElena García-Martín
Jan 2, 2016·Pharmacological Reviews·Janne T BackmanPertti J Neuvonen
Dec 28, 2010·Trends in Pharmacological Sciences·Sarah C Sim, Magnus Ingelman-Sundberg
Dec 15, 2010·British Journal of Clinical Pharmacology·Eline M RodenburgLoes E Visser
Sep 3, 2013·Journal of Clinical Pharmacology·Rocío Prieto-PérezFrancisco Abad-Santos
Oct 13, 2015·Oxidative Medicine and Cellular Longevity·Rajeshwary GhoshAldrin V Gomes
Jun 15, 2013·Mediators of Inflammation·Svatopluk SvětlíkOndřej Slanař
Apr 20, 2016·Arhiv za higijenu rada i toksikologiju·Valon KrasniqiNada Božina
Apr 29, 2015·Pharmacogenomics·José A G AgúndezElena García-Martín
Dec 6, 2011·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Jolanda S van LeeuwenJ Chris Vos
Sep 6, 2014·Frontiers in Pharmacology·José A G AgúndezElena García-Martín
Nov 5, 2014·Frontiers in Cellular Neuroscience·José A G AgúndezElena García-Martín
Oct 18, 2016·Frontiers in Pharmacology·Gemma AmoElena García-Martín
Nov 17, 2017·Monthly Notices of the Royal Astronomical Society·Jean-Christophe LoisonMaryvonne Gerin
Jun 26, 2018·Expert Opinion on Drug Metabolism & Toxicology·Laura CuzzolinVassilios Fanos
Aug 11, 2017·Journal of Clinical Gastroenterology·Pavan K MukthinuthalapatiMarwan Ghabril
Mar 19, 2020·Expert Opinion on Drug Metabolism & Toxicology·Yolanda MacíasJosé A G Agúndez
May 16, 2014·Drug Metabolism and Drug Interactions·Yazun Bashir Jarrar, Su-Jun Lee
Apr 1, 2017·Frontiers in Pharmacology·Tracy A Manuck
Aug 23, 2017·BioMed Research International·Flaminia BardanzelluVassilios Fanos
Oct 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Matilde CapiPaolo Martelletti
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Richard W Grant, Deborah J Wexler
Nov 1, 2013·British Journal of Pain·Roman CreggHiroe Sato
Nov 24, 2019·Surgical Oncology Clinics of North America·Rodney A GabrielRuth S Waterman
Nov 19, 2020·European Journal of Clinical Pharmacology·Giovana M WeckwerthCarlos F Santos
Jul 9, 2021·Frontiers in Pharmacology·L McEvoyM Pirmohamed

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.